Sulfapyridine and Serum in Experimental Type III Lobar Pneumonia

Abstract

Summary

Under the conditions of our experiments the protective value of highly concentrated type specific serum in optimal doses and that of sulfapyridine in optimal doses are approximately equal when the infecting dose of Type III pneumococci is relatively small, resulting in a mortality of 63% in untreated animals. When the infecting dose is sufficiently large to produce an initial mortality of 100%, the mortality after sulfapyridine therapy is significantly less than after serum therapy. Combining serum and sulfapyridine, each in optimal dose, does not reduce mortality below that of sulfapyridine therapy alone in Type III pneumococcic pneumonia, differing in this respect from results previously obtained from similar experiments with Type I pneumococcic pneumonia.